P16 gene mutations in Barrett's esophagus in gastric metaplasia - Intestinal metaplasia - Dysplasia - Adenocarcinoma sequence

Advances in Medical Sciences

Volumn 57, Issue 1, 2012, Pages 71-76

  Mokrowiecka, A ^a   Wierzchniewska LAwska A ^b   Smolarz, B ^c   Romanowicz Makowska, H ^c   Malecka Panas E ^a  

^a N Barlicki University Clinical Hospital No 1 in Lodz ^*  (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

Barrett's esophagus; dysplasia; esophageal adenocarcinoma; gastric metaplasia; intestinal metaplasia; p16 gene

Indexed keywords

PROTEIN P16;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; COMPARATIVE STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS BIOPSY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GOBLET CELL; HUMAN; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MALE; METAPLASIA; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; STOMACH DISEASE;

EID: 84865179925     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.2478/v10039-012-0003-0     Document Type: Article

References (38)

1. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005 Jan 19;97(2):142-6.
2. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol. 2007 Jan;17(1):2-9.
3. Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am. 2002 Apr;11(2):235-56.
4. Powell J, McConkey CC, Gillison WW, Spychal RT. Continuing rising trend in oesophageal adenocarcinoma. Int J Cancer. 2002 Dec;102(4):422-7.
5. Hardie LJ, Darnton SJ, Wallis YL, Chauhan A, Hainaut P, Wild CP, Casson AG. p16 expression in Barrett's esophagus and esophageal adenocarcinoma: Association with genetic and epigenetic alterations. Cancer Letters. 2005 Jan;217(2):221-30.
6. Wild CP, Hardie LJ. Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer. 2003 Sep;3(9):676-84.
7. Jankowski JA, Wright NA, Meltzer SJ, Triadafilopoulos G, Geboes K, Casson AG, Kerr D, Young LS. Molecular evolution of the metaplasia- dysplasiaadenocarcinoma sequence in the esophagus. Am J Pathol. 1999 Apr;154(4):965-73.
8. Hage M, Siersema PD, Vissers KJ, Dinjens WN, Steyerberg EW, Haringsma J, Kuipers EJ, van Dekken H. Genomic analysis of Barrett's esophagus after ablative therapy: persistence of genetic alterations at tumor suppressor loci. Int J Cancer. 2006 Jan;118(1):155-60.
9. Souza RF, Morales CP, Spechler SJ. Review article: A conceptual approach to understanding the molecular mechanisms of cancer development in Barrett's oesophagus. Aliment Pharmacol Ther. 2001 Aug;15(8):1087-100.
10. Werther M, Saure C, Pahl R, Schorr F, Ruschoff J, Alles JU, Heinmoller E. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa - Significance of sampling. Pathol Res Pract 2008 Mar;204(5):285-94.
11. Barrett MT, Sanchez CA, Galipeau PC, Neshat K, Emond M, Reid BJ. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene. 1996 Nov;13(9):1867-73.
12. Weston AP, Banerjee SK, Sharma P, Tran TM, Richards R, Cherian R. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol. 2001 May;96(5):1355-62.
13. Wong DJ, Barrett MT, Stöger R, Emond MJ, Reid BJ. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res. 1997 Jul 1;57(13):2619-22.
14. Tokugawa T, Sugihara H, Tani T, Hattori T. Modes of silencing of p16in development of esophageal squamous cell carcinoma. Cancer Res. 2002 Sep;62(17):4938-44.
15. Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G, Lewin K, Weinstein WM, Antonioli DA, Goldman H. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol. 1988 Feb;19(2):166-78.
16. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell. 2002 Aug;2(2):103-12.
17. Paulson TG, Galipeau PC, Xu L, Kissel HD, Li X, Blount PL, Sanchez CA, Odze RD, Reid BJ. p16 mutation spectrum in the premalignant condition Barrett's esophagus. PLoS One. 2008;3(11):e3809.
18. Lamperska K, Karezewska A, Kwiatkowska E, Mackiewicz A. Analysis of mutations in the p16/CDKN2A gene in sporadic and familial melanoma in the Polish population. Acta Biochim Pol. 2002;49(2):369-76.
19. Pho L, Grossman D, Leachman SA. Melanoma genetics: A review of genetic factors and clinical phenotypes in familial melanoma. Curr Opin Oncol. 2006;18:173-9.
20. Murphy JA, Barrantes-Reynolds R, Kocherlakota R,Bond JP, Greenblatt MS. The CDKN2A database: Integrating allelic variants with evolution, structure, function, and diseaseassociation. Hum Mutat. 2004 Oct;24(4):296-304.
21. Rocco JW, Sidransky D. p16(MTS-1/CDKN2/ INK4a) in cancer progression. Exp Cell Res. 2001 Mar 10;264(1):42-55.
22. Lloyd AC. p53: only ARF the story. Nat Cell Biol. 2000 Mar;2(3):E48-50.
23. Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y. Frequent Somatic Mutation of the MTS1/CDK4I (Multiple Tumor SuppressorlCyclin-dependent Kinase 4 Inhibitor) Gene in Esophageal Squamous Cell Carcinoma. Cancer Res. 1994 Jul;1(13):3396-7.
24. Vieth M, Schneider-Stock R, Röhrich K, May A, Ell C, Markwarth A, Roessner A, Stolte M, Tannapfel A. INK4a-ARF alterations in Barrett's epithelium, intraepithelial neoplasia and Barrett's adenocarcinoma. Virchows Arch. 2004 Aug;445(2):135-41.
25. Debniak T, Scott RJ, Huzarski T, Byrski T, Rozmiarek A, Debniak B, Zaluga E, Maleszka R, Kladny J, Górski B, Cybulski C, Gronwald J, Kurzawski G, Lubinski J. CDKN2A common variants and their association with melanoma risk: A population-based study. Cancer Res. 2005 Feb;65(3):835-9.
26. Debniak T, Scott RJ, Huzarski T, Byrski T, Rozmiarek A, Debniak B, G?ski B, Cybulski C, Medrek K, Mierzejewski M, Masojc B, Matyjasik J, Zlowocka E, Teodorczyk U, Lener M, Klujszo-Grabowska E, Nej-Wolosiak K, Jaworowska E, Oszutowska D, Szymańska A, Szymańska J, Castaneda J, van de Watering T, Suchy J, Kurzawski G, Oszurek O, Narod S, Lubinski J. CDKN2A common variant and multi-organ cancer risk-A population-based study. Int J Cancer. 2006 Jun;118(12):3180-2. E.
27. Ranade K, Hussussian CJ, Sikorski RS, Varmus HE, Goldstein AM, Tucker MA, Serrano M, Hannon GJ, Beach D, Dracopoli NC. Mutations associated with familial melanoma impair p16INK4 function. Nat Genet. 1995 May;10(1):114-6.
28. Lilischkis R, Sarcevic B, Kennedy C, Warlters A, Sutherland RL. Cancer-associated mis-sense and deletion mutations impair p16INK4CDK inhibitory activity. Int J Cancer. 1996 Apr;66(2):249-54.
29. Aitken J, Welch J, Duffy D, Milligan A, Green A, Martin N, Hayward N. CDKN2A variants in a populationbased sample of Queensland families with melanoma. J Natl Cancer Inst. 1999 Mar;91(5):446-52.
30. Debniak T, Górski B, Huzarski T, Byrski T, Cybulski C, Mackiewicz A, Gozdecka-Grodecka S, Gronwald J, Kowalska E, Haus O, Grzybowska E, Stawicka M, Swiec M, Urbański K, Niepsuj S, Waśko B, Gózdz S, Wandzel P, Szczylik C, Surdyka D, Rozmiarek A, Zambrano O, Posmyk M, Narod SA, Lubinski J. A common variant of CDKN2A (p16) predisposes to breast cancer. J Med Genet. 2005 Oct;42(10):763-5.
31. Lal G, Liu L, Hogg D, Lassam NJ, Redston MS, Gallinger S. Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations. Genes Chromosomes Cancer. 2000 Apr;27(4):358-61.
32. Lal G, Liu G, Schmocker B, Kaurah P, Ozcelik H, Narod SA, Redston M, Gallinger S. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germline p16, BRCA1 and BRCA2 mutations. Cancer Res. 2000 Jan;60(2):409-16.
33. Hu YX, Watanabe H, Ohtsubo K, Yamaguchi Y, Ha A, Okai T, Sawabu N. Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. Clin Cancer Res. 1997 Sep;3(9):1473-7.
34. Moskaluk CA, Hruban RH, Kern SE. p16 and K-ras gene mutations in the untraductal precursors of human pancreatic adenocarcinoma. Cancer Res. 1997 Jun;57(11):2140-3.
35. Pollock PM, Pearson JV, Hayward NK. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosomes Cancer. 1996 Feb;15(2):77-88.
36. Gerdes B, Ramaswamy A, Kersing M, Ernst M, Lang S, Schuermann M, Wild A, Bartsch DK. p16 alterations in chronic pancreatitis - indicator for pancreatic cancer. Surgery. 2001 Apr;129(4):490-7.
37. Liu W, Hahn H, Odze RD, Goyal RK. Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium. Am J Gastroenterol. 2009 Apr;104(4):816-24.
38. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol. 2008 Mar;103(3):788-97.